Brain Metastasis from Lung Cancer

Komaki, Ritsuko; Ghia, Amol J.

doi:10.1002/9781118468791.ch38

Cited by 3 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For measuring the metabolite level and distinguishing a tumor from necrotic areas or benign lesions, proton magnetic resonance spectroscopy (MRS) may be used (4). In vivo MRS detects metabolites, such as N-acetylaspartate (NAA), choline (Cho), creatine (Cr), myo-inositol, lactate and lipids, by measuring the spectra of specific isotopes, such as 1 H, 13 C or 31 P (64). Since the metabolite level varies in different parts of the brain and among age groups, it was suggested to measure metabolite ratios, such as Cho/Cr and NAA/Cr, rather than measuring absolute metabolite concentrations (65,66).…”

Section: Current Perspectivesmentioning

confidence: 99%

“…The pathways in the development of malignant gliomas were described in detail by Wen and Kesari (4) and the major genetic alterations in primary and secondary GBM initiation and progression were described by Li et al (12). As regards secondary glioblastomas, the most common origins of brain metastatic lesions are primary cancers of the lung (65%) (13), skin (melanomas, 10-40%) (14), breast and gastrointestinal tract (13). Despite their molecular differences, the two tumor types are morphologically indistinguishable and respond similarly to conventional therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glioma and glioblastoma - how much do we (not) know?

Jovčevska

Kočevar

Komel

2013

Molecular and Clinical Oncology

148

106

View full text Add to dashboard Cite

Section: Current Perspectivesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Glioma and glioblastoma - how much do we (not) know?

Jovčevska

Kočevar

Komel

2013

Molecular and Clinical Oncology

148

106

View full text Add to dashboard Cite

“…Generally, the prognosis of BM is poor. The median survival with standard treatment is 2 months, which involves expensive and invasive procedures, such as systemic treatment with corticosteroids and whole-brain radiotherapy, with or without stereotactic radiosurgery (2). Thus, it is imperative to develop additional effective therapies for patients with BM.…”

Section: Introductionmentioning

confidence: 99%

Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases

Zhang

Yang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer. Recent reports indicated that erlotinib and pemetrexed exerted synergistic effects against lung adenocarcinoma. The available treatment options for lung cancer with brain metastases (BM) are currently limited. In the present study, we investigated the efficacy of the combined administration of erlotinib and pemetrexed in 9 patients with epidermal growth factor receptor (EGFR) wild-type lung adenocarcinoma with BM. Pemetrexed (500 mg/m 2 ) and cisplatin (20 mg/m 2 ) were administered on day 1 and days 1-3, respectively. Erlotinib (150 mg) was administered daily on days 4-20. The 9 patients harbored EGFR wild-type mutation in the primary tumor tissues. With regard to the BM, no patients achieved complete remission, 7 patients exhibited a partial response (PR), 1 had stable disease (SD) and 1 had progressive disease (PD). As regards the extracranial tumors, 3 patients exhibited a PR, 2 had SD, 3 had PD and 1 was not applicable. The performance status and the symptoms improved in 3 patients following treatment. The median progression-free survival for intracranial and extracranial disease control was 179 and 146.5 days, respectively. The median overall survival was 197.4 days. Therefore, erlotinib combined with pemetrexed/cisplatin, was found to be effective in the treatment of patients with EGFR wild-type lung adenocarcinoma.

show abstract

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman,

Karakaya,

Kaplan

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood–brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM. It is important to update the clinical and pathological factors reflected in the survival with real-life data. A multi-center, retrospective database of 306 patients diagnosed with driver mutant NSCLC and initially presented with BM between between November 2008 and September 2022 were analyzed. The median progression-free survival (mPFS) was 12.25 months (95% CI, 10–14.5). While 254 of the patients received tyrosine kinase inhibitor (TKI), 51 patients received chemotherapy as first line treatment. The median intracranial PFS (iPFS) was 18.5 months (95% CI, 14.8–22.2). The median overall survival (OS) was 29 months (95% CI, 25.2–33.0). It was found that having 3 or less BM and absence of extracranial metastases were significantly associated with better mOS and iPFS. The relationship between the size of BM and survival was found to be non-significant. Among patients with advanced NSCLC with de novo BM carrying a driver mutation, long-term progression-free and overall survival can be achieved with the advent of targeted agents with high CNS efficacy with more conservative and localized radiotherapy modalities.

show abstract

Brain Metastasis from Lung Cancer

Cited by 3 publications

References 99 publications

Glioma and glioblastoma - how much do we (not) know?

Glioma and glioblastoma - how much do we (not) know?

Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Contact Info

Product

Resources

About